Indication
For the treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion (UPE) ≥1.0 g/day (or UP/C ≥0.75 g/g).
Medicine details
- Medicine name:
- sparsentan (Filspari)
- SMC ID:
- SMC2847
- Pharmaceutical company
- Vifor Pharma
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Publication due date:
- 08 June 2026
- SMC meeting date:
- 05 May 2026
- Patient group submission deadline:
- 02 March 2026